

Executive Summary of Collaborative Working Project

(1) Astellas Pharma Ltd and Torbay & South Devon NHS Foundation Trust, Torbay Hospital, Lowes Bridge, Torquay, TQ2 7AA

Service Optimisation of the Prostate Cancer Oral Systemic Anti-Cancer Therapy (SACT) pathway

November 2025 to September 2026

Objective:

To undertake a “service review of the Prostate Cancer (PC) Oral SACT Novel Hormone Therapy (NHT) pathway” in partnership with Astellas Pharma Ltd (Astellas), Bionical Health Ltd (Bionical), and Torbay & South Devon NHS Foundation Trust Hospitals to support the re-design of that pathway to optimize the cancer centre’s PC service.

Summary:

New Prostate Cancer cases account for 26% of all new cancer cases in males with 48,500 patients diagnosed every year, this creates a burden on capacity for the NHS within Prostate Cancer clinics in times of restricted NHS budgets.

The PC Oral SACT NHT service optimisation pathway programme will enable cancer centres to work in partnership with Astellas/Bionical to review this part of the pathway to iron out any inefficiencies, wastage, delays & bottlenecks etc. that may be causing an ineffective service.

Astellas are committed to supporting the NHS within Prostate Cancer. By working in partnership, Astellas are at the forefront of driving innovation and change for the positive benefit of patients and assisting the NHS in delivering high standards of care. Working in partnership between Astellas, Bionical and cancer centres, pooling of joint expertise to review this part of the pathway, will support health professionals in their desire to improve patient well-being. The value of the project is £14,208.

Benefits of Project

Patients	• may lead to reduction in waiting times. • potential to increase patient satisfaction. • more efficient services may lead to improved access for patients due to increased patient throughput.
NHS	• service optimisation may lead to improved service delivery and improved capacity within prostate cancer clinics. • reduced risk of missing NHS Cancer Waiting targets, resulting in improved Trust performance through service improvement. • improvement in baseline metrics such as waiting times and other such national targets. • an efficient service will lead to a more sustainable service. • may lead to improved patient satisfaction of the service they receive. • may lead to staff satisfaction and retention.

Astellas Pharma Ltd	• recognition of Astellas offering value added services that benefit NHS prostate cancer services. • service improvement may lead to more throughput of patients which may lead to a benefit of increased use of Astellas products. • enhancing skill base of service re-design expertise in-house.
---------------------------	---